USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Next Generation Electrical Impedance Myography for Neuromuscular…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
1046826
Solicitation Year:
2010
Solicitation Topic Code:
BC
Solicitation Number:
Small Business Information
CONVERGENCE MEDICAL DEVICES, INC.
400 TradeCenter, Suite 5900 Woburn, MA 01801-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: SBIR Phase I: Next Generation Electrical Impedance Myography for Neuromuscular Disease Assessment
Agency: NSF
Contract: 1046826
Award Amount: $149,956.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project will develop an accurate, noninvasive, and cost-effective system for diagnosing and evaluating the severity of neuromuscular diseases. Millions of people in the US suffer from neuromuscular disorders, from generalized diseases like muscular dystrophy and amyotrophic lateral sclerosis to localized conditions including lumbosacral radiculopathy. Treatable neuromuscular disorders require ongoing evaluation for effective management, necessitating accurate diagnostic tools. In disorders where treatments are limited, clinical research trials demand improved methods for assessing disease severity and response to experimental treatment. The overall goal of this project is to develop a novel Electrical Impedance Myography (EIM) system for diagnosing and monitoring neuromuscular diseases. The device is based in the principles of bioimpedance analysis, but it will contain specific innovations that will dramatically improve its accuracy and frequency range relative to existing systems. The research objectives include building a prototype system, verifying its accuracy, and testing its repeatability on human subjects. It is anticipated that the system will quickly provide accurate information about disease condition, improving the treatment of patients with these diseases. The broader impact/commercial potential of this project includes: 1) substantially advancing individual patient care by providing a quick, easy, reproducible and sensitive diagnostic; 2) streamlining clinical trials studying diseases primarily resulting in muscle weakness and dysfunction (including amyotrophic lateral sclerosis, muscular dystrophy, and others) by requiring fewer subjects and shorter periods of study; 3) reducing the cost of disease management; and 4) greatly advancing clinical care of children affected by these disorders by being non-invasive, painless, and requiring only limited cooperation. The proposed EIM system has the potential to exceed the usage of current diagnostic tools, with a potential market exceeding $100 million. The system is planned to initially target pharmaceutical companies that can benefit from it in drug discovery research. The system will then be sold directly to physicians who specialize in the care of those who suffer from these disorders.

Principal Investigator:

Jose L. Bohorquez
6173207998
bohorquez@cmdevices.com

Business Contact:

Jose L. Bohorquez
DPhil
6173207998
bohorquez@cmdevices.com
Small Business Information at Submission:

Convergence Medical Devices, Inc.
503 Washington St. Winchester, MA 01890-1317

EIN/Tax ID: 270517515
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No